Hydrogen/oxygen mixed gas inhalation improves disease severity and dyspnea in patients with Coronavirus disease 2019 in a recent multicenter, open-label clinical trial
by Xu Zou, Nan-Shan Zhong, Ze-Guang Zheng, Ai-Lan Chen, Chun-Hua Wei, Gaung-Yun Guo, Jin-Dong Shi, Pei-Zhen Lai, Wei-Jie Guan, Xiao-Cong Sun
Abstract:
The recent COVID-19 pandemic has highlighted a critical need for effective treatments for respiratory symptoms and disease progression. This multicenter clinical trial explored the potential benefits of hydrogen/oxygen mixed gas (H2-O2) inhalation in alleviating respiratory symptoms in patients with COVID-19. Conducted across seven hospitals in China from January to March 2020, the study involved patients who presented with dyspnea at admission and enrollment. Due to the urgent nature of the pandemic, patients were non-randomly assigned to either the treatment group, which received H2-O2 inhalation, or the control group, which received standard oxygen therapy. The primary outcome was improvement in disease severity, while secondary outcomes included changes in oxygen saturation and symptom scales. Results indicated that H2-O2 inhalation significantly improved respiratory symptoms, such as dyspnea, cough, chest distress, and chest pain, as early as day two of treatment. The study demonstrated that H2-O2 could reduce inspiratory effort and airway resistance, providing a promising adjunct therapy for managing severe respiratory symptoms in COVID-19 patients. However, limitations due to its open-label design and non-randomized assignment suggest the need for further randomized trials to confirm these findings and optimize treatment protocols.
Read more:
https://doi.org/10.21037/jtd-2020-057
Related Articles:
Background: Hydrogen/oxygen therapy contribute to ameliorate dyspnea and disease progression in patients with respiratory diseases. Therefore, we hypothesized that hydrogen/oxygen therapy for ordinary coronavirus disease 2019 (COVID-19) patients might reduce the length of hospitalization and increase hospital discharge rates. Methods:…
Clinical studies had found that hydrogen/oxygen mixed inhalation was beneficial to ameliorate the respiratory symptoms in the adjuvant treatment of patients with COVID-19. We aimed to explore the efficacy of hydrogen/oxygen therapy in favoring the recovery of Omicron SARS-CoV-2 variant…
A global public health crisis caused by the 2019 novel coronavirus disease (COVID-19) leads to considerable morbidity and mortality, which bring great challenge to respiratory medicine. Hydrogen-oxygen therapy contributes to treat severe respiratory diseases and improve lung functions, yet there…
Molecular hydrogen (H2) is potentially a novel therapeutic gas for acute post-coronavirus disease 2019 (COVID-19) patients because it has antioxidative, anti-inflammatory, anti-apoptosis, and antifatigue properties. The aim of this study was to determine the effect of 14 days of H2…
This study investigates the potential therapeutic benefits of hydrogen-rich water (HRW) in treating COVID-19 symptoms through a double-blind randomized placebo-controlled trial involving 24 patients with mild to moderate COVID-19. Participants consumed 1.5 liters of HRW daily for 14 days, where…
Exhaled breath condensate (EBC) is a promising object for biomarkers search as it contains compounds reflecting changes of biological processes caused by various respiratory diseases including COVID-19. Molecular hydrogen was recently discovered as a new effective antioxidant that can restore…
0 Comments